Table 1 Demographic and clinical characteristics of patients with ANCA-IIPs versus patients with MPA-ILDs
Combined (N = 80) | ANCA-IIPs (N = 49) | MPA-ILDs (N = 31) | p value | |
|---|---|---|---|---|
Age, y | 60 (51, 66) | 59 (52, 65) | 62 (47, 67) | 0.812 |
Male | 36 (45.00%) | 24 (48.98%) | 12 (38.71%) | 0.489 |
Follow-up time, m | 40 (27, 58) | 41 (28, 64) | 36 (21, 52) | 0.230 |
Symptoms | ||||
Fever | 26 (32.50%) | 10 (20.41%) | 16 (51.61%) | 0.006* |
Cough | 70 (87.50%) | 42 (85.71%) | 28 (90.32%) | 0.733 |
Dyspnoea | 49 (61.25%) | 29 (59.18%) | 20 (64.52%) | 0.648 |
Fatigue | 11 (13.75%) | 5 (10.20%) | 6 (19.35%) | 0.322 |
Arthralgia | 23 (28.75%) | 15 (30.61%) | 8 (25.81%) | 0.801 |
Signs | ||||
Crackling | 45 (56.25%) | 26 (53.06%) | 19 (61.29%) | 0.497 |
Rash | 10 (12.50%) | 7 (14.29%) | 3 (9.68%) | 0.733 |
Clubbing fingers | 7 (8.75%) | 2 (4.08%) | 5 (16.13%) | 0.102 |
Mechanics hand | 2 (2.50%) | 2 (4.08%) | 0 (0.00%) | 0.519 |
Gottron’s sign | 3 (3.75%) | 2 (4.08%) | 1 (3.23%) | 1.000 |
Systematic manifestations | ||||
Renal | 30 (37.50%) | 0 (0.00%) | 30 (96.77%) | < 0.001* |
Nervous system | 3 (3.75%) | 0 (0.00%) | 3 (9.68%) | 0.055 |
Cardiovascular | 2 (2.50%) | 0 (0.00%) | 2 (6.45%) | 0.147 |
Retinal | 1 (1.25%) | 0 (0.00%) | 1 (3.23%) | 0.388 |
Treatment | ||||
Corticosteroid | 76 (95.00%) | 45 (91.84%) | 31 (100.00%) | 0.154 |
Cyclophosphamide | 32 (40.00%) | 15 (30.61%) | 17 (54.84%) | 0.038* |
Others# | 2 (2.50%) | 2 (4.08%) | 0 (0.00%) | 0.519 |
None | 2 (2.50%) | 2 (4.08%) | 0 (0.00%) | 0.519 |
Outcome | ||||
Death of all cause | 15 (18.75%) | 5 (10.20%) | 10 (32.26%) | 0.019* |
Lung transplantation | 1 (1.25%) | 0 (0.00) | 1 (3.22%) | 0.388 |